Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Shapiro

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Haematologica|May 19, 2018
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II studyCarlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, et al.
Nature Chemistry|February 10, 2025
Synthetic biomolecular condensates enhance translation from a target mRNA in living cellsDaniel Mark Shapiro, Sonal Deshpande, Seyed Ali Eghtesadi, et al.
American Journal of Hematology|March 15, 2016
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibJorge E Cortes, H Jean Khoury, Hagop Kantarjian, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 17, 2006
Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and governmentJoseph Deveaugh-Geiss, John March, Mark Shapiro, et al.
Nature Communications|February 12, 2022
Protein nanowires with tunable functionality and programmable self-assembly using sequence-controlled synthesisDaniel Mark Shapiro, Gunasheil Mandava, Sibel Ebru Yalcin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Annals of Medicine and Surgery (2012)|May 25, 2023
Prospective, multicenter study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (XenMatrix™ AB Surgical Graft) for hernia repair in all centers for disease control and prevention wound classes: 24-month follow-up cohortObeid N Ilahi, George Velmahos, Jeffrey E Janis, et al.
Clinical Pharmacology and Therapeutics|June 4, 2026
Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE InitiativeNatalie Levy, Paige Sheridan, Ulka Campbell, et al.
JAMA Network Open|September 30, 2024
Calibrating Observational Health Record Data Against a Randomized TrialDavid Merola, Ulka Campbell, David Lenis, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Haematologica|May 19, 2018
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II studyCarlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, et al.
Nature Chemistry|February 10, 2025
Synthetic biomolecular condensates enhance translation from a target mRNA in living cellsDaniel Mark Shapiro, Sonal Deshpande, Seyed Ali Eghtesadi, et al.
American Journal of Hematology|March 15, 2016
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibJorge E Cortes, H Jean Khoury, Hagop Kantarjian, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|March 17, 2006
Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and governmentJoseph Deveaugh-Geiss, John March, Mark Shapiro, et al.
Nature Communications|February 12, 2022
Protein nanowires with tunable functionality and programmable self-assembly using sequence-controlled synthesisDaniel Mark Shapiro, Gunasheil Mandava, Sibel Ebru Yalcin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Annals of Medicine and Surgery (2012)|May 25, 2023
Prospective, multicenter study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (XenMatrix™ AB Surgical Graft) for hernia repair in all centers for disease control and prevention wound classes: 24-month follow-up cohortObeid N Ilahi, George Velmahos, Jeffrey E Janis, et al.
Clinical Pharmacology and Therapeutics|June 4, 2026
Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE InitiativeNatalie Levy, Paige Sheridan, Ulka Campbell, et al.
JAMA Network Open|September 30, 2024
Calibrating Observational Health Record Data Against a Randomized TrialDavid Merola, Ulka Campbell, David Lenis, et al.
Pageof 6